April 11, 2003
"A viral load at treatment week four above 450,000 IU/mL and at week 12 above 30,000 IU/mL was 100 percent predictive for virologic nonresponse in all patients," reported Thomas Berg and colleagues of Humboldt University-Berlin. Statistical analysis indicated that being of HCV of genotypes 2 or 3, having high levels of alanine aminotransferase before starting treatment, and having a low viral load at baseline were independent predictors for attaining a sustained virologic response.
"None of the latter three factors were predictive for sustained virologic response when analysis was restricted to the subgroup of genotypes 2- and 3-infected patients," Berg and coauthors wrote. They suggested that by as early as 12 weeks after therapy has begun, doctors can determine whether or not sustained virological response will occur using a HCV RNA cut-off level 30,000 IU/mL. "This algorithm recognizes 53.7 percent of nonresponders previously identified at week 24 of treatment," they said.
The full study, "Prediction of Treatment Outcome in Patients with Chronic Hepatitis C: Significance of Baseline Parameters and Viral Dynamics During Therapy," was published in Hepatology (2003;37(3):600-609).
03.31.03; Sonia Nichols
|Using Saliva as Lube Can Cause Rectal Gonorrhea|
|This Week in HIV Research: Enzyme May Reduce Cardiovascular Disease Risk, and New Insights Into an HIV Vaccine|
|This Week in HIV Research: Determinants of Cognitive Impairment, and Discovery of 'Teenage' Broadly Neutralizing Antibody|
|FDA Approves Descovy, an Updated Version of Truvada -- But Not for PrEP|
|What Should the Next U.S. President Do to Advance the Fight Against HIV?|